CalciMedica Halts Auxora Trial Amid Safety Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 28 Jan 26
Source: PRnewswire
CalciMedica Inc. has seen its stock price drop significantly, hitting a 52-week low in pre-market trading.
The company announced the suspension of its Phase 2 KOURAGE clinical trial for Auxora™ in acute kidney injury patients due to safety concerns raised by the Independent Data Monitoring Committee. Although no deaths related to Auxora or placebo were reported, the trial's suspension may impact future clinical evaluations and the company's stock performance. CalciMedica plans to conduct a comprehensive review of the clinical data to guide future testing of Auxora in acute kidney injury.
This development raises concerns about the company's clinical pipeline and could affect investor confidence moving forward.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
